Medicinal Chemist Consultant: Atherosclerosis, Allergy Respiratory and Inflammation Therapies

Technical Consultant #1423

Experienced medicinal chemist. Delivered 17 active pharmaceutical compounds into development with the most advanced currently in Phase 2 trials.
Served 6 years on clinical development teams and co - chaired the HIV protease development team.
Sustained record of delivering quality API clinical candidates for atherosclerosis, infectious disease, allergy respiratory, inflammation, and cardiovascular therapies.
8 years of pharmaceutical discovery management, including utilizing external chemists, restructuring portfolios, and mentoring 50 chemistry colleagues.
Experienced with most pharmaceutical target types including: Enzymes, proteases, kinases, GPCRs, nuclear hormone receptors, ion channels and projects of unknown mechanism.
Developed and implemented a chemistry department performance management philosophy and career development process as a member of the chemistry executive leadership team.
Licensing team contributor for 8 years performing due diligence on drug candidates.

Pfizer Pharmaceuticals, Groton, CT and Ann Arbor, MI, 1999 - 2007

Senior Director Cardiovascular/Atherosclerosis Chemistry, Ann Arbor, MI

Led a group of 35 - 50 chemists working on FXa, HMGCoA reducase, PPARs, renin, and other targets delivering multiple clinical candidates per year.
Chair of the CV Athero discovery team responsible for therapeutic area deliverables, scientific diligence, project entry and termination, cross discipline alignment and portfolio progression.
Implemented exploratory chemistry meetings that enhanced the scientific rigor of chemical matter triage, reduced project time lines and improved alignment with partner lines.

Inflammation Chemistry: Parallel Synthesis Lab, Groton, CT

Managed a group of approximately 30 (11 Ph.D.) chemists working on P2X7, P38, MMP13, Glucocorticoid Receptor Modulators, and other targets that delivered a clinical candidate per year.
Improved the zone parallel synthesis lab impact by ensuring full integration into project teams.
Stopped a compound from entering development due to unnecessary safety risks.

Manager Allergy and Respiratory Chemistry, Groton, CT

Managed a group of 18 (6 Ph.D.) chemists working on PDE - 4, VLA4, CCR - 3, and other targets that delivered a clinical candidate per year.
Implemented exploratory chemistry meetings enhancing chemical matter diligence, improving biology, chemistry, drug metabolism alignment, and ensuring a sustained portfolio.

Parke - Davis Pharmaceuticals, Ann Arbor, MI, 1989 - 1999

Coordinator of Antiviral chemistry: Worked with the Infectious Disease management team to prioritize projects targeting HIV, HSV, and CMV.
Coordinated 11 chemists (3 Ph.D.) working on targets including Fab - I, Non - peptide HIV - protease, HIV - integrase and others.
Coordinator of the HIV - protease project.
Built a highly functional anti viral chemical team that went from mass screen hits to nominating several development compounds.
Atherosclerosis chemical coordinator of the 15 - lipoxygenase project
Worked on CNS-CCKB antagonists and radical scavengers for Atherosclerosis.

Schering - Plough Pharmaceuticals, Kenilworth, NJ, 1987 - 1989

Experience with atherosclerosis (ACAT inhibitors) and CNS (dopamine D - 1 antagonists).

American Chemical Society; Organic and Medicinal Chemistry Divisions; IUPAC; Sigma Xi, AAAS
22 publications and co-publications. Details available upon request.
20 patents. Details available upon request.